According to a recent study, the number of trials funded annually by the NIH fell from 1,580 to 930 between 2005 and 2015; the NIH budget declined by 20%; and the median size of trials was 64. These numbers suggest that NIH’s mission as a key impartial backer of promising treatments not ready for commercial funding may be threatened. (The Baltimore Sun)